en

PRODUCT DETAIL

Jakavi 15 mg tablety

Code 8516A
MA number EU/1/12/773/008
Product Form: tbl 56x15 mg (blis.PVC/PCTFE/Al)
MA Status: E - Valid centralised marketing authorisation
Type of procedure: EU
Therapeutic Class: 44 - CYTOSTATICA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E Protein kinase inhibitors
L01EJ Janus Associated Kinase (JAK) inhibitors
L01EJ01 Ruxolitinib
Shelf life: 36
Route of admin.: Oral use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 8(3) application - new active substance
MA issued: 23.08.2012
SmPC + PL: European Medicines Agency's database
Safety feature Yes
Data update: 21.09.2021
eu-flag.png sk-flag.png